DoorDash, Inc.

DoorDash, Inc. (NYSE: DASH) owns and runs the DoorDash logistics platform. DoorDash is a platform that links businesses, consumers, and Dashers. Pick up allows customers to place orders ahead of time, skip lines, and pick up their food.

Key Highlights

• The company reported YoY growth of 69.37% in revenues to USD 2.89 billion in FY21 (ended December 31, 2021) compared to USD 4.89 billion in FY20.
• DASH's net loss increased to USD 468 million during FY21 vs. USD 461 million in FY20.
• As of December 31, 2021, the company had cash and cash equivalents of USD 3.76 billion and no outstanding debt.
• Its ROE was -10.0% in FY21 vs. the industry median of 4.9%.
• Negative EBITDA Margin of 4.4% whereas Peer’s Median stood at 1.4%.
• On February 17, 2022, DASH launched rapid grocery delivery. This new service enables consumers faster and more convenient delivery of fresh groceries in under 30 minutes in cooperation with Albertsons, one of the nation's largest food and drug retailers.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• The stock is leaning towards the lower end of its 52-week range of USD 91.96 to USD 257.25.
• DASH's stock price decreased 47.73% and 30.06% in the past six and nine months, respectively.

Technical Price Chart (as of February 18, 2022). Analysis by Kalkine

Conclusion: The company's bottom-line performance deteriorated in FY21 compared to the previous comparable period. Given the lackluster fundamentals, a significant correction in the stock price in the past nine months, and lack of visibility in profitability, we recommend an "Watch" rating on the stock at the closing price of USD 96.21, down 8.40% as of February 18, 2022.

*The reference data in this report has been partly sourced from REFINITIV.

VYNE Therapeutics Inc.

VYNE Therapeutics Inc. (NASDAQ: VYNE) is a specialty pharmaceutical company focused on developing proprietary and differentiated treatments to treat immuno-inflammatory illnesses and uncommon skin diseases with a high unmet medical need.

Key Highlights

• The company reported YoY growth of 24.99% in revenues to USD 4.09 million in Q3FY21 (ended September 30, 2021) compared to USD 3.27 million in Q3FY20.
• VYNE's net loss reduced to USD 21.29 million during Q3FY21 vs. USD 24.71 million in Q3FY20.
• As of December 31, 2021, the company had cash and cash equivalents of USD 52.91 million and no outstanding debt.
• VYNE's Q3FY21 cash cycle of 175 days is significantly higher than the industry median of 118 days.
• Its ROE was -31.8% in Q3FY21 vs. the industry median of 0.5%.
• Negative Net Margin of 520.9% whereas Peer’s Median stood at 6.6%.
• On January 19, 2022, VYNE announced the completion of Phase 1b section of Phase 1b/2a clinical trial evaluating FMX114 to treat mild-to-moderate atopic dermatitis (AD). VYNE's investigational combination gel formulation of tofacitinib and fingolimod is FMX114. The product is being developed to target the source and the cause of inflammation in Alzheimer's disease.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• The stock is leaning towards the lower end of its 52-week range of USD 0.51 to USD 8.98.
• VYNE's stock price decreased 48.75% and 61.65% in the past three and six months, respectively.

Technical Price Chart (as of February 18, 2022). Analysis by Kalkine

Conclusion: Considering the topline growth, long-term profitability issues, technical indicators, and associated risks, we recommend a "Watch" rating on the stock at the closing price of USD 0.5484, up 3.16%, as of February 18, 2022.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.